A high Tumour Mutational Burden (TMB) may be a useful biomarker for assessing patients’ risk of immune-related adverse events (irAEs) during anti-PD1 immunotherapy, a study shows. A retrospective review of irAEs reported for 3661 patients treated with the anti–PD-1 agents nivolumab or pembrolizumab found a significant positive relationship with TMB (defined as the median number ...
Tumour mutational burden predicts irAEs with immunotherapy
By Michael Woodhead
4 Sep 2019